Mircera news from FiercePharma
NewsAmgen prevails against Roche's Mircera
In its ongoing fight with Roche, Amgen now has stronger backing from a federal court. The U.S. District Court in Boston ruled yesterday that Amgen should get a permanent injunction against Roche's... Read more...
Roche appeals Mircera injunction
Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring... Read more...
Mircera judge seeks expert guidance
The judge refereeing the turf battle between Roche and Amgen over anemia meds has taken a time-out to consult the experts. Judge William Young said he's grappling "with complex issues" in the patent... Read more...
Court sends Mircera case to ITC
Another chapter in what's becoming a long Mircera saga: A federal appeals court ruled that Roche could import the anemia drug so long as it wasn't for sale--but sent the case back to the... Read more...
Amgen: Mircera deal would set precedent
Should he or shouldn't he? The judge weighing the case of Amgen v. Roche is getting a lot of unsolicited advice on whether to allow Roche's anemia med Mircera onto the market. Last year, a jury ruled... Read more...
Judge blocks Roche's Mircera--for now
Victory for Amgen--and maybe for Roche, too. The California drug maker persuaded a judge to temporarily ban Roche's competing anemia drug Mircera in the U.S. But the judge also said he'd consider... Read more...
Amgen calls Roche 'snake-oil salesman'
No way, Roche. Amgen rejected a royalty offer from the Swiss drugmaker, which wants to sell an anemia drug that would compete against Amgen's signature blockbusters. Mircera, Roche's version, was
Roche gets Mircera nod, but no launch
It's a victory, but there won't be any party. Roche got the FDA's blessing for its anemia drug Mircera--an event long anticipated by the Swiss drug maker. Instead of moving Mircera quickly onto store... Read more...
Amgen wins patent fight with Roche
Roche's siege on Amgen anemia-drugs territory is ending with a whimper. A jury ruled that the Swiss drug maker's Mircera product... Read more...
Amgen flexes for Roche showdown
"Did I just meet with the mob?" It's not a question you'd expect to hear after a pharma rep comes to call. But according to the New York Times, Amgen is playing hardball to protect its anemia drugs... Read more...
| Press ReleasesPRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy Read more >> |
Get more Mircera coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
